Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind and Randomized Study to Determine the Safety and Tolerability of Multiple Doses of TP-102 in Subjects With Non-Infected and Infected Diabetic Foot Ulcers

Next Previous
X
Search
Trial Profile

A Double-Blind and Randomized Study to Determine the Safety and Tolerability of Multiple Doses of TP-102 in Subjects With Non-Infected and Infected Diabetic Foot Ulcers

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TP-102 (Primary)
  • Indications Acinetobacter infections; Diabetic foot ulcer; Pseudomonal infections; Staphylococcal infections
  • Focus Adverse reactions
  • Acronyms REVERSE
  • Sponsors Technophage

    • Most Recent Events

    • 03 Oct 2022 Status has been changed to completed.
    • 17 Jun 2022 Planned End Date changed from 30 Dec 2021 to 30 Dec 2022.
    • 17 Jun 2022 Planned primary completion date changed from 30 Oct 2021 to 31 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top